The positive rates of autoantibodies against NY-ESO-1 and VCA-IgA in NPC patients with early-stage disease were 47.8% (95% CI, 27.4–68.9%) and 39.1% (95% CI, 20.5–61.2%), respectively, which were significantly higher than those in the normal controls (P<0.0001; Table III). This evidence concerns the gene CD79A and nasopharyngeal carcinoma.